ArticleVirus research2026
Pan-filovirus activity of an IGF2-fused monoclonal antibody: Impairment by IGF1R cross-engagement and rescue via IGF2 Y27L mutation.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFiloviruses (Ebola and Marburg) cause severe high-mortality infectious diseases. Neutralizing antibodies represent promising antiviral candidates, but broadly reactive antibodies against multiple filoviruses are rare. Antibody-ligand fusion strategies that combine conserved glycoprotein-targeting antibodies with IGF2R ligands can mediate endosomal antibody delivery. Previously, we showed that an NPC2-fused AF-03 (an antibody to the GP1 core region) exhibited pan-filovirus neutralization. However, this NPC2 fusion faced quality control challenges and its application is limited by heterogeneous glycosylation, batch inconsistency, and poor CMC feasibility.
methodsHuman IGF2 or its Y27L variant was fused to the N-terminus of the AF-03 light chain via a peptide linker. Cellular attachment was measured by flow cytometry and ELISA. Internalization was assessed by flow cytometry, western blotting and confocal imaging. Neutralizing activity against pseudotyped filoviruses was determined using a luciferase reporter system in vitro.
resultsThe IGF2-fused antibody (termed AF03-IL) exhibited broad-spectrum neutralizing activity against multiple pseudotyped filovirus in vitro. However, its potency, including internalization and neutralization, was much weaker than that of the NPC2-fused antibody (termed AF03-NL). The reduced activity was caused by IGF2 binding to IGF1R on the cell surface. To overcome this limitation, we introduced a single point mutation (Y27L) into the IGF2 domain. This new construct, named AF03-IL
conclusionsThe anti-filovirus activity of IGF2-fused AF-03 is impaired by cross-engagement with IGF1R that is rescued by Y27L introduction. The work also might have implications into the design of IGF2-based protein degradation molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.